Multiple Myeloma | Specialty

Daratumumab Combo Data Published as FDA Considers New Myeloma Indication

October 6th 2016

As the FDA considers a supplemental biologics license application for 2 daratumumab-based triplet regimens in multiple myeloma, the results for 1 of the pivotal phase III studies supporting the sBLA have been published in The New England Journal of Medicine.

Role for MRD in Myeloma Evolves as Novel Agents Increase Response

October 5th 2016

Shaji Kumar, MD, discusses the roles that the recently released updated consensus criteria by the International Myeloma Working Group and MRD testing will play going forward in multiple myeloma.

Dr. George Somlo on Advances in Multiple Myeloma

October 4th 2016

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Approved Myeloma Agents Rapidly Incorporated Into NCCN Guidelines

October 2nd 2016

There have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma, and pivotal data for each agent has supported rapid inclusion into the NCCN treatment algorithms.

Triplet Therapy, ASCT Frontline Standard for Multiple Myeloma

October 2nd 2016

The preferred primary therapy for patients with multiple myeloma is induction therapy with a triplet regimen followed by autologous stem cell transplantation, consolidation, and maintenance.

Dr. Philip L. McCarthy on Maintenance therapy for Multiple Myeloma

September 28th 2016

Philip McCarthy, BA, MD, professor of oncology and internal medicine director, blood and marrow transplant program, Roswell Park Cancer Institute discusses maintenance therapy for multiple myeloma patients that are eligible for transplant.

Frontline Carfilzomib Not Superior to Bortezomib in Phase III Myeloma Study

September 27th 2016

Carfilzomib did not improve progression-free survival compared with bortezomib when used in combination with melphalan and prednisone as a treatment for transplant ineligible patients with newly diagnosed multiple myeloma.

CHMP Issues Positive Opinion for Ixazomib Conditional Approval in Myeloma

September 17th 2016

The CHMP has recommended a conditional approval for ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with multiple myeloma who have received at least 1 prior therapy.

Dr. Jakubowiak on Minimal Residual Disease in Multiple Myeloma

September 15th 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease in multiple myeloma.

New Agents Vie for Role in Multiple Myeloma

September 15th 2016

Despite multiple therapeutic advances in recent years, proteasome inhibitors remain a cornerstone of therapy for multiple myeloma, both newly diagnosed and relapsed and refractory disease.

Dr. Sundar Jagannath on Three-Drug Regimen for Newly Diagnosed Multiple Myeloma

September 12th 2016

Daratumumab Produces Dramatic Responses in Relapsed Light Chain Amyloidosis

September 12th 2016

Almost 90% of patients with previously treated light chain amyloidosis responded to single-agent daratumumab (Darzalex).

Dr. Kumar Discusses the Role of Stem Cell Transplant in Multiple Myeloma

September 10th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the role of stem cell transplant in treating patients with multiple myeloma.

Selinexor Shows Promise in Heavily Pretreated Myeloma

September 7th 2016

Selinexor (KPT-330) demonstrated promising clinical activity in patients with heavily pretreated multiple myeloma.

Ixazomib Benefit Sustained Across Myeloma Subgroups

September 1st 2016

Maria-Victoria Mateos, MD, PhD, provides insight on a subanalysis of the TOURMALINE-MM1 trial, the impact of ixazomib's (Ninlaro's) approval, and the future of triplet combinations in the treatment multiple myeloma.

Dr. Anderson on Future Treatment Landscape of Multiple Myeloma

August 30th 2016

Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.

NEJM Data Highlights Daratumumab Benefit in Refractory Multiple Myeloma

August 27th 2016

Daratumumab (Darzalex) significantly improved progression-free survival when added to bortezomib (Velcade) and dexamethasone for patients with relapsed or refractory multiple myeloma.

Dr. Palumbo on Significance of Daratumumab Triplet in Multiple Myeloma

August 22nd 2016

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.

FDA Approval Sought for Daratumumab Combos in Multiple Myeloma

August 18th 2016

A supplemental biologics license application has been submitted to the FDA for the use of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Dr. Lonial on Daratumumab Plus Pomalidomide in Multiple Myeloma

August 17th 2016

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.